电话 Tel:(86-10) 65028888, 传真 Fax:(86-10) 65028877 北京浩天律师事务所 HYLANDS LAW FIRM 中国北京市朝阳区东三环中路5号财富金融中心 3层、11层、12层、 12F Fortune Financial Center, No.5 Mid Rd, East 3rd Ring, Chaoyang District, Beijing 100020, China 网址:http://www.hylandslaw.com 关于北京三元基因药业股份有限公司 2025年第四次临时股东会之法律意见书 致:北京三元基因药业股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《北京证券交 易所股票上市规则》等现行有效的法律法规、规范性文件,以及北京三元基因 药业股份有限公司章程》(以下简称"公司章程")的规定,北京浩天律师事 务所(以下简称"本所")接受北京三元基因药业股份有限公司(以下简称"公 司")委托,指派本所康乃馨律师、威萌律师(以下简称"本所律师")出席公 司 2025年第四次临时股东会会议(以下简称"本次股东会"),对本次股东会的 相关事项依法 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-115 北京三元基因药业股份有限公司 2025 年第四次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 19 日 2.会议召开地点：公司会议室 3.会议召开方式：现场投票和网络投票相结合的方式 4.会议召集人：董事会 5.会议主持人：董事杨大军 6.召开情况合法合规的说明： 会议的召集、召开、议案审议程序符合《公司法》等有关法律、 法规和《公司章程》的规定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 13 人，持有表决权的股份 总数 59,852,096 股，占公司有表决权股份总数的 49.1356%。 其中通过网络投票参与本次股东会的股东共 5 人，持有表决权的 股份总数 7,368,950 股，占公司有表决权股份总数的 6.0495%。 通过现场和网络参加本次股东会的中小股东（除公司董事、高级 管理人员及其关联方，以及单 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-117 北京三元基因药业股份有限公司 第四届董事会第十一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 19 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 4.发出董事会会议通知的时间和方式：2025 年 12 月 8 日以通讯 方式发出。 5.会议主持人：会议由许大海董事主持。 6.会议列席人员：董事会秘书以及公司其他高级管理人员列席了 会议。 7.召开情况合法合规的说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事程永庆、程十庆、范保群、钱爱民、邵荣光、胡左浩因公务 出差以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于部分募投项目延期及重新论证的议案》 1.议案内容： 具体内容详见公司于 2025 年 12 月 23 ...

北京三元基因药业股份有限公司 拟续聘 2025 年度会计师事务所公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 涉及会计师事务所提供的资料、信息，会计师事务所保证其提供、报送或披 露的资料、信息真实、准确、完整，不得有虚假记载、误导性陈述或者重大遗漏。 一、拟续聘会计师事务所的基本情况 证券代码：920344 证券简称：三元基因 公告编号：2025-113 （一）机构信息 公司拟聘任中审华会计师事务所（特殊普通合伙）为 2025 年年 度的审计机构。 1.基本信息 会计师事务所名称：中审华会计师事务所（特殊普通合伙） 成立日期：2000 年 9 月 19 日 组织形式：特殊普通合伙 注册地址：天津经济技术开发区第二大街 21 号 4 栋 1003 室 首席合伙人：黄庆林 2024 年度末合伙人数量：100 人 2024 年度末注册会计师人数：550 人 2024 年度末签署过证券服务业务审计报告的注册会计师人数： 近三年（最近三个完整自然年度及当年）存在执业行为相关民事 诉讼，在执业行为相关民事诉 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-114 北京三元基因药业股份有限公司 关于召开 2025 年第四次临时股东会通知公告 （提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开基本情况 （一）股东会届次 本次会议为 2025 年第四次临时股东会。 （二）召集人 本次股东会的召集人为董事会。 （三）会议召开的合法合规性 本次股东会的召开符合《公司法》等有关法律、法规及《公司章 程》的规定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 公司同一股东应选择现场投票或网络投票中的一种，如果同一 表决权出现重复投票表决的，以第一次投票表决结果为准。 （五）会议召开日期和时间 1、现场会议召开时间：2025 年 12 月 19 日 14:00。 2、网络投票起止时间：2025 年 12 月 18 日 15:00—2025 年 12 月 19 日 15:00。 登记在册的股东可通过中国证券登记结算有限责任公司（以下简 称"中国结算"）持有人大 ...

证券代码：920344 证券简称：三元基因 公告编号：2025-112 北京三元基因药业股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 11 月 27 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 4.发出董事会会议通知的时间和方式：2025 年 11 月 16 日以通讯 方式发出。 5.会议主持人：会议由程永庆董事长主持。 6.会议列席人员：董事会秘书以及公司其他高级管理人员列席了 会议。 7.召开情况合法合规的说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 董事程十庆因工作原因缺席，委托董事程永庆代为表决。 董事范保群、钱爱民、邵荣光、胡左浩因工作原因以通讯方式参 与表决。 二、议案审议情况 （一）审议通过《关于续聘中审华会计师事务所（特殊普通合伙）的 议案》 4.提交股东 ...

Investment Rating - The report indicates a positive investment sentiment towards the North Exchange market, particularly in the new energy sector, suggesting a potential for growth and investment opportunities [4][27]. Core Insights - The North Exchange A-share trading volume reached 23.87 billion yuan on November 13, 2025, an increase of 3.952 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1529.62, up 2.62% [8][4]. - A total of 282 companies were listed on the North Exchange, with 229 stocks rising, 9 remaining flat, and 44 declining. The top five gainers included Tianhong Lithium Battery (30.0%), Meideng Technology (13.6%), and Derui Lithium Battery (12.1%) [18][4]. - The report highlights that the new energy industry chain performed strongly, with significant contributions from lithium battery chemicals and diversified chemical sectors, indicating a robust market interest [4][21]. Summary by Sections Market Review - On November 13, 2025, the North Exchange A-share trading volume was 23.87 billion yuan, marking a 39.52 billion yuan increase from the previous day. The North Exchange 50 Index closed at 1529.62, reflecting a 2.62% increase, with a PE_TTM of 72.59 [8][4]. - The North Exchange specialized index closed at 2531.88, up 1.86% [8]. Stock Performance - Among the 282 companies, 229 saw an increase in stock prices, while 44 experienced declines. The top five gainers were Tianhong Lithium Battery (30.0%), Meideng Technology (13.6%), and Derui Lithium Battery (12.1%) [18][4]. - Conversely, the top five decliners included Ruixing Co. (-4.7%) and Chicheng Co. (-3.5%) [18][4]. Investment Recommendations - The report suggests that the North Exchange market is experiencing heightened activity, driven by increased investor interest in the new energy sector. The report emphasizes the long-term investment value of companies in specialized and innovative sectors [4][27]. - The report notes that the global monetary easing cycle continues, favoring small-cap stocks, which aligns with the characteristics of companies listed on the North Exchange [4].

Core Points - As of November 12, the total margin financing and securities lending balance on the Beijing Stock Exchange (BSE) is 7.844 billion yuan, a decrease of 54.58 million yuan from the previous trading day, marking a continuous decline for seven consecutive trading days [1] - The stocks with the highest margin financing balances include Jinbo Biological, Shuguang Digital Innovation, and Better Energy, with latest financing balances of 408 million yuan, 335 million yuan, and 297 million yuan respectively [1] - A total of 106 stocks on the BSE received net margin purchases on November 12, with 21 stocks having net purchases exceeding 1 million yuan, led by Litong Technology with a net purchase of 10.0662 million yuan [1][2] Industry Analysis - The industries with the most stocks receiving net margin purchases over 1 million yuan include machinery equipment, electric power equipment, and basic chemicals, with 7, 4, and 2 stocks respectively [2] - On November 12, the average decline for stocks with net margin purchases exceeding 1 million yuan was 0.65%, with the top gainers being Sanyuan Gene, Beiyikang, and Zhongfang Biao, which increased by 12.45%, 4.08%, and 4.02% respectively [2] - The average turnover rate for stocks with net margin purchases exceeding 1 million yuan on November 12 was 4.74%, with the highest turnover rates recorded for Rongyi Precision, Jinhua New Materials, and Xin Ganjiang at 16.26%, 14.42%, and 13.73% respectively [2] Stock Performance - The stocks with the highest increases in margin financing balances on November 12 include Litong Technology, Sanyuan Gene, and Lingge Technology, with increases of 10.0662 million yuan, 9.4553 million yuan, and 6.6036 million yuan respectively [3][4] - The stock with the highest margin financing balance on November 12 was Litong Technology, which had a balance of 115.58 million yuan despite a decline of 6.88% in its stock price [3] - Other notable stocks with significant margin financing increases include Tongli Co., Liancheng CNC, and Gebijia, with respective increases of 6.1667 million yuan, 5.9608 million yuan, and 5.3861 million yuan [3][4]

Market Overview - On November 12, the total trading volume of stocks on the Beijing Stock Exchange reached 913 million shares, with a total transaction value of 19.915 billion yuan, a decrease of 5.84 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 128 stocks closed higher, accounting for 45.55% of the total, with notable gainers including Sanyuan Gene, Danna Biological, and Luqiao Information, which rose by 12.45%, 9.99%, and 7.21% respectively [1] - Conversely, 147 stocks closed lower, with the largest declines seen in Huifeng Diamond, Gaisi Food, and Litong Technology, which fell by 9.06%, 7.31%, and 6.88% respectively [1] Trading Activity - A total of 60 stocks had transaction values exceeding 100 million yuan, with the highest transaction values recorded for Andar Technology, Zhu Laoliu, and Better Ray, at 566.33 million yuan, 535.27 million yuan, and 490.44 million yuan respectively [1] - In terms of trading activity, 24 stocks had a turnover rate exceeding 10%, with 5 stocks exceeding 20%. Additionally, 46 stocks had turnover rates between 5% and 10%, while 189 stocks had turnover rates between 1% and 5% [1] - The stocks with the highest turnover rates included Danna Biological, Zhu Laoliu, and Gaisi Food, with turnover rates of 39.96%, 35.73%, and 30.83% respectively [1] Notable Stocks - The closing prices and performance of notable stocks include: - Andar Technology: 8.19 yuan, down 1.92%, turnover rate 15.32%, transaction value 566.34 million yuan [1] - Zhu Laoliu: 25.12 yuan, down 3.38%, turnover rate 35.73%, transaction value 535.27 million yuan [1] - Better Ray: 34.55 yuan, down 2.48%, turnover rate 1.29%, transaction value 490.44 million yuan [1] - Sanyuan Gene: 33.15 yuan, up 12.45%, turnover rate 7.52%, transaction value 27.64 million yuan [1] - Danna Biological: 85.45 yuan, up 9.99%, turnover rate 39.96%, transaction value 239.83 million yuan [1]

Core Insights - The first domestically developed gene engineering Class I new drug, human interferon α1b (Yunde Su), is showing unique potential in cancer treatment, emphasizing "Chinese wisdom" in the field [1] Group 1: Event Overview - The "2025 Annual Academic Salon of Academicians and Experts" was held by Sanyuan Gene Pharmaceutical Co., Ltd. in Beijing, focusing on the innovative application of human interferon α1b in treating malignant tumors [1] - The event was guided and funded by the Beijing Association for Science and Technology, gathering top oncology experts from various prestigious institutions [3] Group 2: Strategic Value of Old Drugs - Academician Hou Yunde, known as the "father of Chinese interferon," highlighted that while interferon is an old drug, interferon α1b is a new drug with significant advantages in cancer treatment, including the ability to improve efficacy through higher dosages and expand clinical indications [4] - Continuous innovation by clinical experts and Sanyuan Gene in new formulations and administration methods for interferon has established a high-quality brand in China [4] Group 3: Clinical Data and Research Findings - Experts shared significant research results on the efficacy of interferon α1b in treating melanoma, particularly in the context of its unique characteristics compared to Western treatments [5] - A new high-level randomized controlled clinical research plan was announced, indicating that combination therapy based on human interferon α1b is effective and safe for various types of melanoma [5] Group 4: Expert Consensus and Guidelines - The latest expert consensus on the treatment of melanoma with interferon α1b was presented, confirming its safety and efficacy through numerous cases [6] - The treatment protocol for melanoma using interferon α1b has been officially included in the 2025 edition of the Chinese Anti-Cancer Association (CACA) melanoma guidelines, marking a significant recognition of domestically developed innovative drugs [6] Group 5: Future Directions - A high-level dialogue session was held to explore future research directions and application potential of interferon α1b, showcasing the event as a platform for academic achievements and promoting the value of original research drugs in cancer treatment [7]